Approach to and Treatment of Goiters

dc.creatorMedeiros-Neto, Geraldo
dc.creatorCamargo, Rosalinda Y.
dc.creatorTomimori, Eduardo K.
dc.date.accessioned2013-10-30T16:13:59Z
dc.date.accessioned2018-07-04T16:05:59Z
dc.date.available2013-10-30T16:13:59Z
dc.date.available2018-07-04T16:05:59Z
dc.date.created2013-10-30T16:13:59Z
dc.date.issued2012
dc.identifierMEDICAL CLINICS OF NORTH AMERICA, PHILADELPHIA, v. 96, n. 2, supl. 1, Part 3, pp. 351-+, MAR, 2012
dc.identifier0025-7125
dc.identifierhttp://www.producao.usp.br/handle/BDPI/36916
dc.identifier10.1016/j.mcna.2012.01.010
dc.identifierhttp://dx.doi.org/10.1016/j.mcna.2012.01.010
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1631396
dc.description.abstractThe main causes of simple diffuse goiter (SDG) and multinodular goiter (MNG) are iodine deficiency, increase in serum thyroid-stimulating hormone (TSH) level, natural goitrogens, smoking, chronic malnutrition, and lack of selenium, iron, and zinc. Increasing evidence suggests that heredity is equally important. Treatment of SDG and MNG still focuses on L-thyroxine-suppressive therapy surgery. Radioiodine alone or preceded by recombinant human TSH stimulation is widely used in Europe and other countries. Each of these therapeutic options has advantages and disadvantages, with acute and long-term side effects.
dc.languageeng
dc.publisherW B SAUNDERS CO-ELSEVIER INC
dc.publisherPHILADELPHIA
dc.relationMEDICAL CLINICS OF NORTH AMERICA
dc.rightsCopyright W B SAUNDERS CO-ELSEVIER INC
dc.rightsclosedAccess
dc.subjectSIMPLE GOITER
dc.subjectMULTINODULAR GOITER
dc.subjectSONOGRAPHY
dc.subjectSURGERY
dc.subjectL-THYROXINE THERAPY
dc.subjectRADIOIODINE ABLATION
dc.titleApproach to and Treatment of Goiters
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución